George Washington University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, George Washington University sits in the top decile of US sponsors by registered trial count (#208 of 15,742 sponsors by registered trial count).

133 total trials 24 currently recruiting 88 completed early-phase tilt top decile by trial count

George Washington University: 133 sponsored US clinical trials, 24 recruiting.

George Washington University sponsors 133 registered US clinical trials on ClinicalTrials.gov, 24 of them currently recruiting, and 88 completed. 11 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Postpartum Hemorrhage, with 2 trials.

Top-decile sponsor footprint

George Washington University ranks in the top decile of sponsors by registered trial count (#208 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 55/100

88 of 102 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

133 total, page 2 of 3

TERMINATED NA

Dose of Vestibular Rehabilitation for Vestibular Hypofunction

NCT04851184

TERMINATED Phase 4

Postoperative Pain Control Following Renal Transplant

NCT05044429

COMPLETED NA

Digital Media for Cancer Control (to Prevent Vaping and Smoking Behavior)

NCT04867668

COMPLETED NA

MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

NCT04724291

COMPLETED

The PPHgb Study: Non-Invasive Hemoglobin Measurement

NCT05046964

TERMINATED

Personalization of Immunosuppressive Treatment for Organ Transplant Recipients

NCT05747053

COMPLETED

Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19

NCT05063812

COMPLETED NA

A Multicomponent Intervention to Increase HIV Risk Perceptions and PrEP Initiation Among Black Men Who Have Sex With Men

NCT04533386

TERMINATED Early Phase 1

PVB vs Ketamine/Lidocaine in Rib Fracture Patients

NCT04413799

COMPLETED

The Selfie Study- Assessing Novel Markers for Cervical Cancer Screening From Self-collected Samples

NCT04423679

COMPLETED NA

An Educational Video's Impact on the Induction of Labor Experience

NCT04537260

TERMINATED NA

VR Breaks on Shift-worker Alertness

NCT04132141

COMPLETED NA

Reducing Sugar-sweetened Beverage Consumption Among Children

NCT04025060

COMPLETED NA

Testing an Online Intervention to Improve Parents' Communication With Gay and Bisexual Sons About Sex and HIV

NCT04018573

COMPLETED NA

Water Up@ At Home: An Intervention to Replace Sugary Drinks With Water

NCT05159622

TERMINATED Phase 1

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

NCT03829930

TERMINATED NA

Assessing the Sensitivity of "SureTouch™" in Women Undergoing Diagnostic and Screening Mammography

NCT04397029

COMPLETED

Pathways Project: Kidney Supportive Care

NCT04125537

COMPLETED NA

Advance Care Planning Coaching for Patients With Chronic Kidney Disease

NCT03506087

COMPLETED NA

Capsule Endoscopy for HEmorrhage in the ER

NCT03458000

COMPLETED NA

Taking Action to Thrive - A Healthy Lifestyle Intervention Pilot Study

NCT03478345

COMPLETED Phase 2

Prevention of Postpartum Hemorrhage With Tranexamic Acid

NCT03287336

COMPLETED NA

Comparative Effectiveness Feasibility Trial for Insomnia Among Breast Cancer Survivors

NCT03328169

COMPLETED NA

Effect of Social Media Support and Financial Incentives on PrEP Adherence

NCT03078153

COMPLETED NA

Low-calorie Sweeteners and Adipose Signaling

NCT03125356

COMPLETED

Burnout Among Members of AAGL

NCT03078296

COMPLETED Phase 4

Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

NCT02964585

COMPLETED Phase 2

Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep

NCT03148899

COMPLETED NA

Video Discharge Instructions (VDI) as Adjuncts to Written Discharge Instructions in the Emergency Department

NCT02882256

COMPLETED NA

The Effect of Partial Bladder Filling on Post-operative Time to Void in Minimally Invasive Gynecologic Procedures

NCT02741531

COMPLETED NA

Proficiency Based Robotics Training Curriculum: Skill Acquisition & Transferability of Skills to Live Porcine Models

NCT02895347

COMPLETED NA

Point-of-Care Follow-Up With Primary Care After Emergency Department Discharge

NCT02740348

COMPLETED Phase 4

Abatacept in Juvenile Dermatomyositis

NCT02594735

COMPLETED Early Phase 1

Oxytocin on HR in Sleep Apnea Patient

NCT02564068

COMPLETED Phase 4

Linagliptin's Effect on CD34+ Stem Cells

NCT02467478

COMPLETED NA

Quit4Baby Evaluation

NCT02412865

COMPLETED Phase 1

Use of Intravenous Tranexamic Acid During Myomectomy

NCT02620748

COMPLETED NA

Social Media Obesity Treatment for College Students

NCT02342912

COMPLETED

Partnership and Dignity: a Mixed-methods Survey on Supporting and Retaining Uganda's Village Health Teams

NCT02374580

COMPLETED

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

NCT02887495

COMPLETED Phase 4

Photodynamic Therapy for Papulopustular Rosacea

NCT02075671

COMPLETED NA

Changing the Healthcare Delivery Model

NCT02093234

COMPLETED

Muscle Ultrasound for Sarcopenia Leading to Early Detection

NCT02319850

COMPLETED NA

The Application of Sterile Water to the Skin of Extremely Low Birth Weight (ELBW) Infants

NCT02052284

COMPLETED NA

Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)

NCT02383407

COMPLETED NA

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

NCT05684016

COMPLETED Phase 4

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

NCT02024477

COMPLETED NA

Evaluation of Immediate v. Delayed CT/NG Test for Treatment in the ED

NCT01989130

COMPLETED NA

Evaluate Initial Success Rate of Ultrasound Guided Versus Landmark Approach For Peripheral Intravenous Access

NCT01859559

COMPLETED NA

CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)

NCT01721226

← Previous Page 2 of 3 Next →

What is open in the George Washington University pipeline

24 recruiting of 133 indexed (18% open); 88 completed (66%).

Phase mix: 11 late (III/IV) vs 18 early (I/II) (early-phase heavy).

Top condition: Postpartum Hemorrhage (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

George Washington University: open-pipeline peers nationwide

Peers matched on 133 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

George Washington University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 0%5%10%15%20%25% Total trials Recruiting share George Washington UniversityMillennium PharmaceuticalsNational Institute on Aging (NIA)The Miriam HospitalRhode Island HospitalHospital for Special Surgery, New YorkUniversity of California, BerkeleyWest Virginia UniversityChildren's Hospital of Philadelphia
George Washington University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

George Washington University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 133 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this George Washington University page

133 registered trials is a research-attention snapshot, not an endorsement of George Washington University or any single study.

  • 24 of George Washington University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Postpartum Hemorrhage is the condition George Washington University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Postpartum Hemorrhage trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. George Washington University pipeline card: 133 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.